ReviewOncoTargets and therapy2014
Cerium oxide nanoparticles in cancer.
Review in OncoTargets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The biomedical application of inorganic metal nanoparticles in aging and aging-associated diseases.Journal of advanced research · 2025Pooled it
- Doxorubicin-Loaded Cerium Oxide Nanoparticles Suppress Cell Proliferation, Migration and Invasion of Triple-Negative Breast Cancer Cells.ACS omega · 2026Article
- Rare-Earth Elements at the Interface of Chemistry and Cancer Therapy.Molecules (Basel, Switzerland) · 2026Review
- Exploration of Cytotoxicity and Antibacterial Activities of M-CeoChemistryOpen · 2025Article
- Exploring the Cytotoxic and Redox-Modulatory Effects of Nanoceria in MCF7 Breast Cancer Cells Using Integrated Molecular and Proteomic Analyses.Antioxidants (Basel, Switzerland) · 2025Article
- Sericin-coated MnOScientific reports · 2025Article
- New insights of cerium oxide nanoparticles in head and neck cancer treatment.Scientific reports · 2025Article
- A methotrexate labelled dual metal oxide nanocomposite for long-lasting anti-cancer theranostics.Materials today. Bio · 2025Article
- Novel Flavin Mononucleotide-Functionalized Cerium Fluoride Nanoparticles for Selective Enhanced X-Ray-Induced Photodynamic Therapy.Journal of functional biomaterials · 2024Article
- Green mediated synthesis of cerium oxide nanoparticles by usingRSC advances · 2024Article
- Synthesis of ultrasmall cerium oxide nanoparticles in deep eutectic solvent and their application in an electrochemical sensor to detect dopamine in biological fluid.Mikrochimica acta · 2024Article
- Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Frontiers in bioengineering and biotechnology · 2024Review
- Novel Cerium(IV) Coordination Compounds of Monensin and Salinomycin.Molecules (Basel, Switzerland) · 2023Article
- A Brief Review on Cerium Oxide (CeOMicromachines · 2023Review
- Inorganic Nanomaterials Used in Anti-Cancer Therapies:Further Developments.Nanomaterials (Basel, Switzerland) · 2023Review
- Alleviating the hypoxic tumor microenvironment with MnOJournal of nanobiotechnology · 2023Article
- Nanoceria: an innovative strategy for cancer treatment.Cellular and molecular life sciences : CMLS · 2023Review
- Advancements in nanoparticle-based treatment approaches for skin cancer therapy.Molecular cancer · 2023Review
- Mitogen-like Cerium-Based Nanoparticles ProtectInternational journal of molecular sciences · 2023Article
- How Synthesis of Algal Nanoparticles Affects Cancer Therapy? - A Complete Review of the Literature.International journal of nanomedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the development of many nanomedicines designed for tumor therapy, the diverse abilities of cerium oxide nanoparticles (CONPs) have encouraged researchers to pursue CONPs as a therapeutic agent to treat cancer. Research data have shown CONPs to be toxic to cancer cells, to inhibit invasion, and to sensitize cancer cells to radiation therapy and chemotherapy. CONPs also display minimal toxicity to normal tissues and provide protection from various forms of reactive oxygen species generation. Differential cytotoxicity is important for anticancer drugs to distinguish effectively between tumor cells and normal cells. The antioxidant capabilities of CONPs, which enable cancer therapy protection, have also resulted in the exploration of these particles as a potential anticancer treatment. Taken together, CONPs might be a potential nanomedicine for cancer therapy and this review highlights the current research into CONPs as a novel therapeutic for the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.